Le Lézard
Classified in: Health, Business
Subjects: LIC, TRI

PharmaMar and Boryung Pharm Sign A Licensing Agreement for Zepsyre® (lurbinectedin) in Korea


MADRID, November 7, 2017 /PRNewswire/ --

PharmaMar (MCE: PHM) has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Zepsyre® (lurbinectedin), if approved, in South Korea. Under the terms of the agreement, PharmaMar receives a non-disclosed upfront payment and will be eligible for additional remunerations upon achieving regulatory and sales milestones. PharmaMar will retain exclusive production rights and will sell the product to Boryung Pharm for commercial use, if approved.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

Zepsyre® is currently in late-stage clinical development for platinum-resistant ovarian cancer and for small-cell lung cancer. After results obtained in clinical trials about BRCA 2-associated metastatic breast cancer and endometrial cancer, PharmaMar also plans to initiate a pivotal phase III study in each of those indications.  

According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, "This is our second strategic agreement with Boryung Pharm and we are very pleased with our business partner. This new agreement will allow Zepsyre® to reach the Korean market, if approved, in the hands of one of the leading companies in the field of oncology in this country."

Boryung Pharm Chief Executive Officer, Mr. Tae-Hong Choi said, "We are very pleased to have our second licensing deal with PharmarMar. This licensing deal will strengthen our existing strong relationship with PharmaMar and demonstrate our high confidence in PharmaMar`s development pipeline." He added: "Zepsyre® may provide new therapies in various types of solid tumors, including a platinum-resistant ovarian cancer, BRCA 2-associated metastatic breast cancer and small-cell lung cancer. We look forward to making these new therapies available in South Korea, if approved."

Contact: Media Relations (+34-638-79-62-15) and Investor Relations (+34-914-44-45-00)

SOURCE PharmaMar


These press releases may also interest you

25 avr 2024
AZZ Inc. Announces Pricing of its Public Offering of Common Stock
AZZ Inc. , the leading independent provider of hot-dip galvanizing and coil coating solutions, today announced the pricing of its underwritten public offering of 4,000,000 shares of common stock at a public offering price per share of $70.00, for...

25 avr 2024
Moore Law PLLC Investigating LOTZ, EDR, DCGO and MRCY; Shareholders are Encouraged to Contact the Firm
CarLotz, Inc.  Accused of Misleading Investors On March 29, 2024, the defendants' motion to dismiss in the pending securities class...

25 avr 2024
TSX Venture Exchange Stock Maintenance Bulletins
TSX VENTURE COMPANIES BULLETIN V2024-1200 LEONOVUS INC. ("LTV.WT")BULLETIN TYPE:  Warrant Expiry-DelistBULLETIN DATE:  April 25, 2024TSX Venture Tier 2 Company Effective at the opening, May 2, 2024, the Share Purchase Warrants of the Company will...

25 avr 2024
GREENBROOK TMS REPORTS FISCAL YEAR 2023 OPERATIONAL AND FINANCIAL RESULTS
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
Dominion Lending Centres Inc. Announces Sale of its Interest in Impact Communications
Dominion Lending Centres Inc. ("DLCG" or the "Corporation") is pleased to announce that it has completed a sale of its 52% interest in Cape Communications International Inc. ("Impact") for aggregate cash proceeds of $3.71 million (the "Purchase...

25 avr 2024
Orbia Announces First Quarter 2024 Financial Results
Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) ("the Company" or "Orbia") today released unaudited results for the first quarter of 2024. Orbia's first quarter performance reflects the continued weakness in the market environment,...

More news about Business...


News published on and distributed by: